Supplementary Fig S1.

The gating strategies are shown for T and NK cell populations (A), for T-cell activation (B) and proliferation (C) markers and for TCR- $\gamma\delta$ T-cells (D) and TCR- $\gamma\delta$ activation and proliferation markers (E).





Fig S1 continued



Supplementary Fig S2. A. Percentages of CD14+ CD16- classical monocytes (cMo), CD14+ CD16+ intermediate monocytes (iMo) and CD14- CD16+ non classical monocyes (ncMo). Percentages are calculated in live, CD3-, CD66b-, HLA-DR+ cells in the COVID-19 patient and in healthy controls (n=6). B. Percentages of blood monocyte-derived M1 (CD14+ CD80+ CD68+) and M2 (CD14+ CD163+ CD68+) macrophages are shown for the COVID-19 patient and healthy controls. **C-E** Neutrophil degranulation measured as MFI of CD11b (secretory vesicles), CD66b (secondary granules) and CD63 (primary granules) is shown for the patient and healthy controls (n=4). Neutrophils were immunostained in whole blood, followed by erythrocyte lysis with ACK buffer and fixation with 4% PFA prior for analysis by flow cytometry. Blood monocytes and monocyte-derived macrophages were stained from PBMCs isolated by FicoII gradient as described in the methods section.



Supplementary Fig S3.

Representative flow cytometry plots are shown for the COVID-19 patient (day 23) and an age-matched healthy control.



Supplementary Fig S4.

A. Serum IgG response to Pseudomonas aeruginosa (PA) protein outer membrane porin F (OprF) was assessed in healthy controls (n=2), in the COVID-19 patient (n=1) and in patients with diagnosis of Cystic Fibrosis and PA infection in the lung (n=2). Data are presented mean ± SEM. **B.** Plasma IgG responses to SARS-CoV-2 Spike and N were assessed in the COVID-19 patient at 5 timepoints. For reference we also show levels from serum of healthy control donors (HC=5), healthy pre-pandemic control donors (Pre; n=6) and a pooled serum (PS; n=3) control per plate (collected from 3 RT-PCR-confirmed convalescent donors). The optical density (OD) at 492 nm was corrected for background (620 nm) and for the blank values.



Methods. A. The PA antigen OprF was diluted in coating buffer, added to the wells of MaxiSorp flat-bottom 96-Well immunoplates (Thermo Fisher Scientific, USA) and incubated for 2h at 37°C. Immunoplates were blocked with 1% BSA/PBS for 1h at 37°C. Sera from were diluted and added to the immunoplates in triplicate and incubated at 4°C overnight. Biotin mouse anti-human IgG (BD Pharmingen, USA) was added to the plate and incubated for 1h at RT. Streptavidin-HRP (R&D Systems, UK) was added and for 30 mins at RT. ELISAs were developed using TMB substrate. Results were recorded using a Multiskan™ GO Microplate Spectrophotometer (Thermo Scientific, USA) and expressed as absorbance value (OD 450). OprF antigen was produced using the recombinant vector pSUMO-OprF as described previously (Quigley K et al AJRCCM).

B. ELISA methods were based on the protocols for measuring SARS-CoV-2 seroconversion outlined in Amanat *et al* (Nat Med, 2020) and Stadlbauer *et al* (Curr Prot Micro; 2020) with modifications. A full-length trimeric stabilized version of the SARS-CoV-2 Spike protein was expressed in insect cells using the MultiBac baculovirus expression system and affinity purified, whereas the SARS-CoV-2 N protein was expressed in, and purified from, *E. coli*. High-binding plates (MaxiSorp, NUNC) were coated with either 10 ug/ml Spike or 20 ug/ml N protein in PBS and left overnight at 4°C followed by blocking for 1 hour (3% BSA/0.1% Tween/PBS). Dilution buffer (1% BSA/0.1% Tween/PBS) containing serum or plasma samples or controls (final dilution 1 in 450, adjusting for dilution of plasma if obtained via PBMC collection) was then added to wells in duplicate and left for 2h at RT. Goat anti-human IgG-HRP (Southern Biotech) was added in dilution buffer for 1 hr, followed by development with OPD solution (Sigma) as per the manufacturer's instructions. Development was quenched after 30 minutes using 3M HCl and absorbance measured at 492 and 620 nm using a BMG FLUOstar Omega Spectrophotometer.

Supplementary Table S1. Details of the antibodies used for the flow cytometry experiments.

Antibody	Company	clone	concentration used
Brilliant Violet 650™ anti-human CD4	Biolegend	RPA-T4	0.625:50
Brilliant Violet 605™ anti-human HLA-DR	Biolegend	L243	2.5:50
Brilliant Violet 711™ anti-human CD38	Biolegend	HIT2	2.5:50
Zombie Aqua™ Fixable Viability Kit	Biolegend		1:1000
Brilliant Violet 421™ anti-human Ki-67	Biolegend	Ki-67	3:50
PE-CF594 Mouse Anti-Human CD56	BD Biosciences	NCAM16.2	0.5:50
PE anti-human CD16	Biolegend	3G8	2.5:50
APC/Cyanine7 anti-human CD8	Biolegend	SK1	3:50
Alexa Fluor [®] 700 Mouse Anti-Human CD3	BD Biosciences	UCHT1	1:50
V450 Mouse Anti-Human IFN-γ	BD Biosciences	B27	3:50
Alexa Fluor® 488 anti-human CD107a (LAMP-1)	Biolegend	H4A3	2.25:150
PE/Dazzle™ 594 anti-human TNF-α	Biolegend	MAb11	3:50
Brilliant Violet 785™ anti-human CD163	Biolegend	GHI/61	2.5:50
Brilliant Violet 605™ anti-human CD14	Biolegend	M5E2	2.5:50
Alexa Fluor [®] 488 anti-human CD68	Biolegend	Y1/82A	5:50
PE/Dazzle™ 594 anti-human CD66b	Biolegend	G10F5	5:50
PE anti-human TCR γ/δ	Biolegend	B1	2.5:50
APC/Cyanine7 anti-human CD16	Biolegend	3G8	0.5:50
APC anti-human CD80	Biolegend	2D10	2.5:50
PerCP-Cy™5.5 Mouse Anti-Human CD3	BD Biosciences	UCHT1	2:50